BIOCYTOGEN-B - An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section

does not make any statement or completeness, and expressly expressly expresses that it will not have any liability arising out of or in reliance on the whole or any part of this announcement. assumes no responsibility for any losses caused by relying on such content.

BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.

Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (a joint stock limited company incorporated in the People's Republic of China) (Stock code: 2315)

Overseas regulatory announcement

This announcement is made by Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (the "Company") under the Hong Kong Stock Exchange Published in accordance with the provisions of Rule 13.10B of the Rules Governing the Listing of Securities of Limited Company. This is to list the Company on the Shanghai Stock Exchange

The following announcements published on the website are for reference only.

1. "Announcement of Resolutions of the Second Extraordinary Shareholders Meeting of Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. in 2026"

2. "Beijing Zhonglun Law Firm About Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. in 2026

Legal Opinion of the Second Extraordinary Shareholders Meeting"

By order of the board of directors Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. Chairman, Chief Executive Officer and Executive Director

Shen Yuelei

Hong Kong, June 25, 2026

As of the date of this announcement, the Company’s Board of Directors includes Dr. Shen Yuelei, Chairman, Chief Executive Officer and Executive Director;

Executive Director Dr. Ni Jian; Non-executive Directors Dr. Zhou Kexiang, Ms. Zhang Leidi and Dr. Liu Hongkang; Independent Non-Executive Directors Executive directors Mr. Hua Fengmao, Dr. Yu Changyuan and Ms. Liang Xiaoyan; and employee director Ms. Li Yan.

Securities code: 668888779966 Securities abbreviation: Baibaiaosaitutu Announcement number: 22002266--002299

BioBio Ossay Tutu ((Beijing)) Medical and Pharmaceutical Technology Co., Ltd.

22002266 Second Provisional Shareholders Meeting Resolutions Announcement

The company's board of directors and all directors guarantee that the announcement does not contain any false records or misleading statements.

or major omissions, and shall bear legal responsibility for the authenticity, accuracy and completeness of its content in accordance with the law.

Important content reminder:

 Whether any motions were rejected at this meeting: None

11. Meeting convening and attendance status

(1) Time of the shareholders’ meeting: June 25, 2026

(2) The shareholders' meeting will be held at: Conference Room 1F-5, Building 2, No. 12, Baocan South Street, Daxing District, Beijing

(3) Common shareholders, special voting rights shareholders, preference shareholders whose voting rights have been restored and those attending the meeting

The number of voting rights it holds:

1. Number of shareholders and proxies attending the meeting 286

Number of common shareholders 286

Among them: Number of A-share shareholders 285 Number of shareholders of overseas listed foreign shares 1

2. Number of voting rights held by shareholders attending the meeting 301,190,627

Number of voting rights held by ordinary shareholders 301,190,627

Among them: the number of voting rights held by A-share shareholders 267,953,919

Number of voting rights held by shareholders of overseas listed foreign shares 33,236,708

3. The number of voting rights held by shareholders attending the meeting accounts for the number of voting rights of the company. 67.3958 Proportion (%) The ratio of the number of voting rights held by ordinary shareholders to the number of voting rights of the company 67.3958

(%)

Among them: the number of voting rights held by A-share shareholders accounts for the number of voting rights of the company 59.9586 Proportion (%)

The number of voting rights held by shareholders of overseas listed foreign shares accounts for the company’s 7.4372 Proportion of the number of voting rights (%)

(4) Whether the voting method complies with the provisions of the Company Law and the company's articles of association, and the status of the shareholders' meeting, etc.

This meeting was convened by the company's board of directors and chaired by Chairman Shen Yuelei. The meeting uses on-site voting and online voting

A combined voting method (only for A-share shareholders). The convening and convening procedures of this shareholders’ meeting, and the

The qualifications of the persons attending the meeting and the qualifications of the convener, the voting procedures and voting results of the meeting are all in compliance with the provisions of the People's Republic of China

The provisions of the Company Law of the Republic and the Articles of Association of Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.

(5) Attendance of company directors and board secretaries

1. The company has 9 current directors and 9 people are present;

2. Wang Yongliang, Secretary of the Company’s Board of Directors, attended this meeting as a non-voting delegate; other senior management personnel also attended this meeting as a non-voting delegate.

3. Review and review of motions

(1) Non-cumulative voting proposals

1. Proposal title: Proposal on formulating the "Remuneration Management System for Directors and Senior Management Personnel"

Review result: Passed

Voting status: Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 301,186,744 99.9987 1,000 0.0003 2,883 0.0010

Including: A shares 267,952,919 99.9996 1,000 0.0004 0 0.0000

Overseas listed foreign capital 33,233,825 99.9913 0 0.0000 2,883 0.0087 shares

2. Proposal Name: Proposal on the General Authorization to Repurchase the Company’s H Shares Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 301,186,524 99.9986 0 0.0000 4,103 0.0014 Including: A shares 267,953,919 100.0000 0 0.0000 0 0.0000

Overseas listed foreign capital 33,232,605 99.9877 0 0.0000 4,103 0.0123 shares

3. Proposal name: Proposal on the general authorization to issue additional H shares of the company

Review result: Passed

Voting status: Agree Disagree Abstain

Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 299,018,788 99.2789 2,168,956 0.7201 2,883 0.0010 Among them: A 267,921,133 99.9877 32,786 0.0123 0 0.0000 shares

Overseas listing 31,097,655 93.5642 2,136,170 6.4271 2,883 0.0087 foreign stocks

4. Proposal Name: Proposal on the Company and its Subsidiaries to Apply for Comprehensive Credit Lines and Provide Guarantees Review result: Passed

Voting status:

Agree Disagree Abstain Shareholder Type Ratio Ratio Ratio Number of votes Number of votes Number of votes (%) (%) (%) Ordinary shares 299,303,059 99.3733 1,884,685 0.6257 2,883 0.0010

Among them: A 267,923,901 99.9887 30,018 0.0113 0 0.0000 shares Overseas listing 31,379,158 94.4111 1,854,667 5.5802 2,883 0.0087 foreign stocks

(2) When major matters are involved, the voting status of less than 5% of shareholders should be explained.

Agree Disagree Abstain motion Bill name Proportion Proportion Proportion Serial number Number of votes Number of votes Number of votes (%) (%) (%) 2 Regarding buyback companies 147,8 100.00 0 0.0000 0 0.0000 H shares General 17,95 00 Sexual empowerment bill 9 3 Regarding the issuance of additional companies 147,7 99.977 32,78 0.0222 0 0.0000 H shares General 85,17 8 6 Sexual Authorization Bill 3 4 About the company and its subsidiaries 147,7 99.979 30,01 0.0204 0 0.0000 Comprehensive company application 87,94 6 8

Credit limit and withdrawal 1 Proposal for providing guarantee

(3) Explanation of relevant circumstances regarding voting on motions

1. Resolutions 2, 3, and 4 of this shareholders’ meeting are special resolutions. Shareholders who have attended this shareholders’ meeting (including

It was reviewed and approved by more than two-thirds of the total number of shares with valid voting rights held by shareholders (including shareholders’ agents). Proposal 1 is a general vote.

To pass resolutions, the shares with valid voting rights held by shareholders who have attended this shareholders’ meeting (including shareholders’ agents)

Adopted by more than half of the total number of votes.

2. The votes of A-share small and medium-sized investors were counted separately for resolutions 2, 3, and 4 of this shareholders’ meeting.

3. Lawyers and lawyers witness the situation

4. The law firm witnessing this shareholders’ meeting: Beijing Zhonglun Law Firm

Lawyers: Wei Haitao, Liu Yichuan

2. Lawyer’s concluding comments:

The convening and holding procedures of this shareholders' meeting of the company comply with the "Company Law", "Shareholders' Meeting Rules" and other laws, regulations,

The relevant provisions of normative documents and the "Articles of Association", the qualifications of those attending the meeting and the qualifications of the convener are legal

Valid, the voting procedures and results of the meeting are legal and valid.

Announcement is hereby made.

Board of Directors of Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.

June 26, 2026

Beijing Zhongzhong Lunlun Law Firm

About Baiaosai Tutu ((Beijing)) Medical and Pharmaceutical Technology Co., Ltd.

The second and second extraordinary shareholders' meeting of the year 2026

legal opinion letter

June 2026

Beijing Zhongzhong Lunlun Law Firm

About Baiaosai Tutu ((Beijing)) Medical and Pharmaceutical Technology Co., Ltd.

The second interim shareholders’ meeting in 2026

legal opinion letter

To:: Baibaiaosai Tutu ((Beijing)) Medical and Pharmaceutical Technology Co., Ltd.

According to the agreement between Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Company") and Beijing

The provisions of the "Perennial Legal Service Agreement" signed by Zhonglun Law Firm (hereinafter referred to as "the Firm") and

As assigned by our firm, our lawyers conducted a review of the company’s second extraordinary shareholders’ meeting in 2026 (hereinafter referred to as “the shareholders’ meeting”). Witness the legality of the association") and issue legal opinions.

This legal opinion is based on the Company Law of the People's Republic of China (hereinafter referred to as the "Company Law"),

Securities Law of the People's Republic of China (hereinafter referred to as the "Securities Law"), China Securities Regulatory Commission

"Rules for Shareholders Meetings of Listed Companies" of the China Securities Regulatory Commission (hereinafter referred to as the "China Securities Regulatory Commission") (hereinafter referred to as the "Shareholders' Meetings")

"Rules of the Association") and other currently effective relevant laws, regulations and normative documents as well as "Biocyto (Beijing)"

Issued in accordance with the provisions of the Articles of Association of Pharmaceutical Technology Co., Ltd. (hereinafter referred to as the "Articles of Association").

In order to issue this legal opinion, our lawyers reviewed the relevant documents and materials of the company's shareholders' meeting.

Our lawyers have received the following guarantee from the company, that is, they have provided the necessary information that our lawyers consider necessary to issue this legal opinion.

The required materials, original materials, copies, photocopies and other materials, and oral testimony are all true and accurate.

Accurate and complete requirements, relevant copies and photocopied materials are consistent with the original original materials.

In this legal opinion, our lawyers only discuss the convening, convening procedures, and attendance of this shareholders’ meeting.

Whether the qualifications of personnel, the qualifications of the convener, the voting procedures of the meeting, and the voting results are in compliance with the "Company Law" and "Shareholders"

legal opinion

"Meeting Rules" and other laws, regulations, normative documents and the "Articles of Association" and other laws, regulations, and the provisions of the "Articles of Association", and will not

Express opinions on the content of the motions under consideration and the truthfulness and accuracy of the facts or data expressed in those motions.

Our firm and our lawyers comply with the Securities Law and the Administrative Measures for Law Firms Engaging in Securities Legal Business.

and "Law Firms' Securities Legal Business Practice Rules (Trial)" and other provisions and the date of issuance of this legal opinion

Facts that have occurred or existed in the past, strictly performed legal duties, followed diligence, responsibility and good faith

In accordance with the principles, sufficient verification has been carried out to ensure that the facts identified in this legal opinion are true, accurate and

Complete, the concluding opinions expressed are legal and accurate, and there are no false records, misleading statements or major

If you omit it, you will bear corresponding legal liability.

This legal opinion is only for the purpose of witnessing the legality of matters related to the company’s shareholders’ meeting and shall not

for any other purpose.

Our lawyers comply with the requirements of the law and in accordance with the recognized professional standards, ethics and diligence of the legal profession. In the spirit of due diligence, we have verified and verified the relevant documents and facts provided by the company, and now issue a legal

The legal opinion is as follows:

11. Convening procedures for this second shareholder meeting

12. The company held the 18th meeting of the second board of directors on June 4, 2026, and reviewed and approved

"Proposal on Proposing to Convene the Company's Second Extraordinary Shareholders' Meeting in 2026".

2. On June 5, 2026, the company released an information disclosure website and media designated by the China Securities Regulatory Commission.

The "Notice on Convening the Second Extraordinary Shareholders' Meeting in 2026" provides information on the time and place of this shareholders' meeting. points, matters to be considered at the meeting, attendees at the meeting, meeting registration methods, contact person’s name and phone number, etc.

The item was notified to all shareholders in the form of an announcement.

After review, our lawyers believe that the time, method and content of the company’s notice of this shareholders’ meeting are based on

And the company's convening procedures for this shareholders' meeting comply with the "Company Law", "Shareholders' Meeting Rules" and other laws, regulations and rules.

Standard documents and the provisions of the Articles of Association.

22. The convening of this second shareholder meeting

legal opinion

1. This shareholders' meeting will adopt a combination of on-site voting and online voting.

2. The on-site meeting of this shareholders’ meeting will be held at 14:00 on June 25, 2026 at Baocen, Daxing District, Beijing.

Held in the conference room 1F-5, Building 2, No. 12 South Street. The meeting was chaired by Mr. Shen Yuelei, chairman of the company.

3. The online voting time for this shareholders’ meeting is: June 25, 2026. Among them: Passed Shanghai Certificate

The specific time for online voting in the stock exchange’s online voting system is 9:15-9 on June 25, 2026: 25, 9:30-11:30 and 13:00-15:00; the specific time for voting through the Internet voting platform is 2026

June 25th, 9:15-15:00.

After review, our lawyers believe that the convening of this shareholders’ meeting is in compliance with the Company Law and the Rules of Shareholders’ Meetings.

and other laws, regulations, normative documents and the provisions of the Articles of Association.

33. Qualifications of the attendees and convener of this shareholders’ meeting

34. Shareholders attending the live meeting

After verification, a total of 0 shareholders and shareholders' agents attended the company's on-site shareholders' meeting, representing

There are 0 shares, accounting for 0% of the company’s total voting shares.

2. Shareholders participating in online voting

According to online data provided by the Shanghai Stock Exchange, the total number of shareholders participating in online voting at this shareholder meeting

285 shareholders are qualified to participate in voting through the online voting system, and their identities have been confirmed by the Shanghai Stock Exchange

The trading system performs authentication. A total of 1 H-share shareholder and shareholder representative participated in the online voting at this shareholders' meeting.

Our lawyers are unable to verify the qualifications of shareholders who vote online. All shareholders who participate in online voting are qualified

Subject to the provisions of laws, administrative regulations, normative provisions and the Articles of Association, relevant shareholders attending the meeting

Eligible.

3. The company's directors, board secretary and other senior managers and witnessing lawyers attended the shareholder meeting

Yes.

4. The convener of this shareholders' meeting is the company's board of directors.

legal opinion

After review, our lawyers believe that the qualifications of the attendees and the convener of this shareholders’ meeting are in compliance with the requirements of the

The provisions of laws, regulations, normative documents such as "Judiciary" and "Shareholders' Meeting Rules" and the "Articles of Association".

44. The voting procedures and voting results of this shareholder meeting

This shareholders' meeting reviewed the proposals included in the notice of the shareholders' meeting, and voted on-site and online.

way. There were 0 shareholders voting on site this time, and other shareholders voted through online voting. Waiting for online voting form After the voting, the company tallied the voting results.

Witnessed by our lawyers, the voting results of the resolutions reviewed at this shareholders’ meeting are as follows:

1. ． "Proposal on the Establishment of the Salary and Remuneration Management System for Directors, Senior Management Personnel"

Voting results: 301,186,744 shares were approved, accounting for 10% of the shares with valid voting rights held by shareholders attending the meeting.

99.9987%; opposed 1,000 shares, accounting for 0.0003% of the valid voting shares held by shareholders attending the meeting; abandoned

2,883 shares, accounting for 0.0010% of the valid voting shares held by shareholders attending the meeting.

The voting result of the motion was passed.

2. ． "Proposal on the General Authorization Authority to Repurchase H Shares of the Company"

Voting results: 301,186,524 shares were approved, accounting for 10% of the shares with valid voting rights held by shareholders attending the meeting.

99.9986%; opposed 0 shares, accounting for 0.0000% of the valid voting shares held by shareholders attending the meeting; abstained

4,103 shares, accounting for 0.0014% of the valid voting shares held by shareholders attending the meeting.

Voting results of small and medium investors: Agree 147,817,959 shares, accounting for 147,817,959 shares held by small and medium shareholders attending the meeting 100.0000% of the shares with valid voting rights; 0 shares were opposed, accounting for the shares with valid voting rights held by the small and medium-sized shareholders attending the meeting

0.0000% of the shares; 0 shares abstained from voting, accounting for 0.0000% of the valid voting shares held by the small and medium-sized shareholders attending the meeting.

The voting result of the motion was passed.

3. ． "Proposal on the General Authorization of Additional Issuance of H Shares of the Company"

legal opinion

Voting results: 299,018,788 shares were approved, accounting for 10% of the shares with valid voting rights held by shareholders attending the meeting.

99.2789%; opposed 2,168,956 shares, accounting for 0.7201% of the valid voting shares held by shareholders attending the meeting;

2,883 shares abstained from voting, accounting for 0.0010% of the valid voting shares held by shareholders attending the meeting.

Voting results of small and medium investors: Agree 147,785,173 shares, accounting for 147,785,173 shares held by small and medium shareholders attending the meeting

99.9778% of the shares with valid voting rights; 32,786 shares were opposed, accounting for the valid votes held by small and medium-sized shareholders attending the meeting

0.0222% of the shares with voting rights; 0 shares abstained from voting, accounting for 0.0222% of the shares with valid voting rights held by the small and medium-sized shareholders attending the meeting.

0.0000%.

The voting result of the motion was passed.

4. ． "Proposal on Applying for a Comprehensive Credit Line and Providing Guarantee to the Company and its Subsidiaries"

Voting results: 299,303,059 shares were approved, accounting for 10% of the shares with valid voting rights held by shareholders attending the meeting.

99.3733%; opposed 1,884,685 shares, accounting for 0.6257% of the valid voting shares held by shareholders attending the meeting;

2,883 shares abstained from voting, accounting for 0.0010% of the valid voting shares held by shareholders attending the meeting.

Voting results of small and medium investors: Agree 147,787,941 shares, accounting for 147,787,941 shares held by small and medium shareholders attending the meeting 99.9796% of the shares with valid voting rights; 30,018 shares were opposed, accounting for the valid votes held by small and medium-sized shareholders attending the meeting

0.0204% of the shares with voting rights; 0 shares abstained from voting, accounting for 0.0204% of the shares with valid voting rights held by the small and medium-sized shareholders attending the meeting.

0.0000%.

The voting result of the motion was passed.

55. Conclusions and comments

To sum up, our lawyers believe that the convening and convening procedures of the company’s current shareholders’ meeting comply with the Company Law.

"Rules of Shareholders' Meeting" and other laws, regulations, normative documents and relevant provisions of the "Articles of Association", attend the meeting The qualifications of the meeting members and the qualifications of the convener are legal and valid, and the voting procedures and voting results of the meeting are legal and valid.

This legal opinion is made in triplicate originals and will take effect after being signed by our lawyers and stamped with the official seal.

[No text below]

legal opinion

(This page is "Beijing Zhonglun Law Firm About Biocytogen (Beijing) Pharmaceutical Technology Co., Ltd.

The signature page of the Legal Opinion of the Second Extraordinary Meeting of Shareholders in 2026)

Beijing Zhonglun Law Firm (stamped)

Person in charge: Handling lawyer:

Zhang Xuebing Wei Haitao

Handling lawyer:

Liu Yichu

June 25, 2026